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Bilateral, Full-thickness Macular Holes While Undergoing Chemotherapy
Abstract
Background
Background: Bilateral, full-thickness macular holes are a rare condition that can substantially affect
quality of life. Macular hole diagnosis and treatment is key for these patients.
Case Report
Report: A 71 year old Caucasian male presented with a chief complaint of distance blur in both eyes,
worsening over the past 1-2 weeks. He had no diagnosis of diabetes. He added that his prostate cancer
had spread and that his last treatment ended 9 days ago. He was ultimately diagnosed with bilateral, fullthickness macular holes. Referral to a retinal specialist for surgical management yielded good results.
Conclusion
Conclusion: This is the first case report documenting bilateral macular holes in a patient with these
systemic meds to date. More research on any potential ocular side effects of these medications is
recommended.

Keywords
macular hole, prostate cancer, chemotherapy

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This case report is available in Optometric Clinical Practice: https://athenaeum.uiw.edu/optometric_clinical_practice/
vol4/iss1/6

Dieter et al.: Bilateral, Full-thickness Macular Holes as Undergoing Chemo

INTRODUCTION
Full-thickness macular holes can quickly impact a patient’s daily life due to their
effect on central vision. Blurred vision, metamorphopsia, or a central scotoma are
common presenting symptoms. The prevalence of full-thickness macular holes is
approximately 3:1000, with 70% of patients being female.1,2 The age of onset for
both males and females is most common in the 7th to 8th decade.¹ Full-thickness
macular holes are most commonly caused by vitreous-mediated anteroposterior or
tangential forces on the retinal surface. 2 A full-thickness hole interrupts all neural
retinal layers from the internal limiting membrane to the retinal pigment
epithelium. 3

Classification of macular holes is useful for surgical management and prognosis.
In 2013, the International Vitreomacular Traction Study (IVTS) Group developed
an Optical Coherence Tomography (OCT)-based anatomic classification system for
disease of the vitreomacular interface.2 The IVTS system is presented in Table 1.
This new system is based on the minimum hole width.2 The aperture size is
measured using the caliper function on spectral-domain OCT devices.2 The
minimum hole width is measured at the narrowest hole point in the mid retina.2
Clinical Stages

Vitreomacular Adhesion

Vitreomacular Traction
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Attributes

Comments

Has been called stage 0 in
the past when the
Vitreous adhesion to
contralateral eye has a
central macula with no
FTMH;
normal
demonstrable
retinal
appearance on clinical
morphologic changes
examination;
no
symptoms
Vitreous adhesion to
central macula with
May or may not have
demonstrable changes by
yellow changes in central
OCT but no full
macula on examination;
thickness
tissue
can be referred to as
dehiscence; may include
impending macular hole
the following: tissue
if there is a FTMH in the
cavitation,
cystoid
contralateral eye
changes in the macula,
loss of foveal contour,
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elevation of the fovea
above RPE
Hole ≤250 μm, may be
round or have a flap
Small
Full-Thickness adherent to the vitreous;
Macular Hole
operculum may or may
not be present
Hole >250 but ≤400 μm;
may be round or have a
Medium Full-Thickness
flap adherent to the
Macular Hole
vitreous; operculum may
or may not be present
Hole >400 μm; vitreous
Large
Full-Thickness more likely to be fully
Macular Hole
separated
from
the
macula

Visual acuity may be
relatively good; optimal
size for successful repair
by
pharmacologic
vitreolysis; very high
probability of success
with vitrectomy surgery
High probability of
success with vitrectomy
surgery
Slightly less probability
of successful closure
with vitrectomy surgery

Table 1: Clinical Stages of the International Vitreomacular Traction Study Classification System
for Vitreomacular Adhesion, Traction, and Macular Hole.2 FTMH = full-thickness macular hole;
RPE= retinal pigment epithelium

The occurrence of bilateral, simultaneous, full-thickness macular holes is rare.
The risk of fellow eye involvement at 5 years is approximately 10% and the mean
interval time between onset of the first full-thickness macular hole to the onset of a
macular hole in the fellow eye is 26.1 months.1,3 We report a unique case of
bilateral, simultaneous full-thickness macular holes in a male while undergoing
metastatic prostate cancer treatment. Given the bilateral presentation, it was
necessary to further investigate for an underlying cause.
CASE REPORT
A 71-year-old white male presented with blurred distance vision in both eyes of
two weeks duration. He noted difficulty reading street signs while driving and
written text on television. He was being monitored bi-annually for glaucoma
suspicion due to optic nerve asymmetry and had a remote history of welder’s flash
in both eyes. The patient’s ocular history was otherwise unremarkable. Three years
prior to presentation he was diagnosed with prostate cancer and eight weeks prior
to his visit to the eye clinic he was diagnosed with metastatic lesions to his spine.
For his metastatic disease he had undergone 5 radiation sessions, with the last
treatment being 9 days prior to his initial eye examination. He began oral therapy
with enzalutamide 40 mg capsules, taking 4 capsules by mouth every 24 hours.
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After 4 weeks of this regimen, the patient was also given an injection of leuprolide
acetate suspension (Eligard®). At week 6, he was referred to the eye clinic due to
blurred vision of one week duration. With the recent addition of two new
medications that coincided with his visual symptoms, these medications were
investigated and will be discussed further.
His medical history included hypertension, hyperlipidemia, and a recent urinary
tract infection. His current medication regimen included: alfuzosin HCL 10 mg for
benign prostatic hyperplasia, finasteride 5 mg for benign prostatic hyperplasia,
docusate sodium 50 mg/sennosides 8.6 mg for constipation, hydrochlorothiazide
25 mg for hypertension, venlafaxine HCL 50 mg for anxiety, zolpidem tartrate 5
mg for insomnia, and potassium phosphate 155 mg/sodium biphosphate 852
mg/sodium phosphate 130 mg, vitamin D3 1000 units, vitamin B12 1000 mg, and
calcium 200 mg supplements. He had no known allergies to medications.
The patient’s Snellen visual acuities measured 20/30+ in the right eye and 20/20in the left eye at his eye examination 1 month prior. The 20/30+ acuity in the right
eye was stable and attributed to a mild cataract. At the patient’s full exam 8 months
prior, his macular OCT scan showed normal foveal contour in both eyes. At
presentation, his best corrected visual acuities were reduced to 20/50 in the right
eye and 20/50- in the left eye. Refractive error was stable at +0.25-1.75 x 080 right
eye and -0.50-1.50 x 105 left eye. Pupils were equal, round, and reactive to light
without an afferent pupillary defect. Biomicroscopy of the anterior segment was
unremarkable and intraocular pressures were 17 mm Hg in both eyes. A dilated
eye exam revealed mild nuclear and cortical cataracts in both eyes. Cup-to-disc
ratios of the optic nerve were 0.45 in the right eye and 0.2 in the left
eye. Examination of the maculae showed patchy epiretinal membranes in both eyes
with a faint 1/8 DD red foveal spot in the right eye (Fig 1). Vessels were of normal
course and caliber in both eyes. The peripheral retinae were flat and intact.
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Figure 1: Color and red free fundus photographs of the right eye and left eye at the time of the small
macular hole diagnosis, exhibiting mild epiretinal membrane in each eye and a subtle red foveal
spot in right eye.

Spectral domain imaging of the maculae was obtained using the Zeiss Cirrus HD
5000 OCT to help reveal the cause of the reduced vision. Imaging showed
vitreomacular traction and macular hole formation, with minimum hole widths
measuring 107 microns for the right eye and 190 microns for the left eye. Based
on IVTS staging, the patient was diagnosed with vitreomacular traction and
secondary small full-thickness macular holes in each eye (Fig 2).

Figure 2: OCT macular cube scan at visit 8 months prior
showing a normal foveal contour of each eye.
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Figure 3: OCT macular cube scan of each eye
at initial presentation showing vitreomacular
traction with small full-thickness macular holes
in the left eye more than right.

The patient was educated that he no longer met the state of Ohio nighttime driving
standards of 20/40 vision or better in at least one eye. The patient agreed to the
restriction of daytime only driving. An Amsler grid was dispensed for daily use
and the patient was educated to call if sudden changes occurred while observing the
grid. Given the concerning nature of bilateral macular holes which were affecting
his quality of life, a referral was made to a retinal specialist for evaluation and
management.
Due to the patient’s chemotherapy schedule, the patient was seen by the retinal
specialist 8 weeks after his initial optometry evaluation. His visual acuity was
reduced to 20/100 right eye (pinhole 20/60) and 20/400 left eye (pinhole 20/200).
The OCT HD 5-line raster scan showed resolution of vitreomacular traction, but
progression to large full-thickness macular holes, left eye worse than right (Fig 4).
A vitrectomy with epiretinal membrane peel and gas tamponade was recommended
by the retinal specialist. Risks of vitrectomy, including cataract progression and
residual distortion even after successful surgery were discussed. The patient was
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agreeable to surgery. The surgical plan included a macular hole repair, starting
with the right eye once he was given medical clearance by his oncologist.
Due to the patient’s chemotherapy schedule, the patient was seen by the retinal
specialist 8 weeks after his initial optometry evaluation. His visual acuity was
reduced to 20/100 right eye (pinhole 20/60) and 20/400 left eye (pinhole 20/200).
The OCT HD 5-line raster scan showed resolution of vitreomacular traction, but
progression to large full-thickness macular holes, left eye worse than right (Fig 4).
A vitrectomy with epiretinal membrane peel and gas tamponade was recommended
by the retinal specialist. Risks of vitrectomy, including cataract progression and
residual distortion even after successful surgery were discussed. The patient was
agreeable to surgery. The surgical plan included a macular hole repair, starting
with the right eye once he was given medical clearance by his oncologist.

Figure 4: OCT HD 5 Line Raster of right eye and left eye at 8 weeks illustrating
resolution of vitreomacular traction and progression to large full-thickness macular
hole both eyes.

A shared clinical decision was made to postpone the retinal surgery until his
chemotherapy was completed. The patient was seen for an office visit by the retinal
specialist a few months later; acuities remained stable at 20/100 right eye and
20/400 left eye. The patient was now able to proceed with a vitrectomy the
following week to repair the full-thickness macular holes, starting with the right
eye.
The patient underwent a successful vitrectomy with an epiretinal membrane peel
and gas tamponade of the right eye. He had good surgical results with a bestcorrected visual acuity of the right eye measuring 20/40 at his 8 week post-operative
visit. As shown in Figure 5, the OCT showed an anatomically closed macular hole.
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The plan was to proceed with vitrectomy in the left eye during the next break in
chemotherapy.

Figure 5: OCT HD 5 Line Raster right eye after
vitrectomy with epiretinal membrane peel showing
an anatomically closed macular hole, clear vitreous
and residual retinal surface irregularity, in comparison
to a large full-thickness macular hole left eye at 8 week
follow up visit.
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DISCUSSION
Our patient presented with the rare finding of new bilateral full-thickness macular
holes while undergoing chemotherapy and radiation treatment for metastatic
prostate cancer. The role of vitreomacular traction in the etiology of macular holes
is widely known.1 Risk factors of full-thickness macular holes include high myopia,
trauma, ocular surgery, electric shock, and some systemic medications.1,4 High
myopia can lead to increased anteroposterior or tangential forces on the retinal
surface. These tractional forces may predispose a patient to the formation of
macular holes. Laser-assisted in situ keratomileusis (LASIK) surgery may induce
postoperative changes in the vitreomacular interface due to the mechanical stretch
of the vitreous produced by the suction ring.4 This, combined with the shock waves
generated by the excimer laser, may subsequently provoke macular hole
formation.4 It should be noted that many patients undergoing LASIK have an
anatomic predisposition to macular holes given underlying high myopia.4 There
has also been evidence of bilateral macular holes after a patient was struck by
lightning.5
Absent high myopia, LASIK, electrical shock, or recent trauma, it was necessary
to investigate other causes, including medications and the patient’s radiation
history. Systemic medications, particularly those that may cause cystoid macular
edema or increased vitreomacular traction, have been implicated in the formation
of macular holes. Tamoxifen is a widely known chemotherapy agent linked to
maculopathy. Tamoxifen is a selective estrogen receptor modular used for breast
cancer treatment.6 Eisner A et al proved that foveae of women using anastrozole
(Arimidix®) appeared to be subjected to more tractional force than the foveae of
women not using any hormonal medication.7 Another treatment for breast cancer is
docetaxel (Taxotere®) which has also been linked to maculopathy.8 These
chemotherapy agents are not used in the treatment of metastatic prostate cancer. A
literature review did not yield any evidence of macular holes as known side effects
of chemotherapy agents commonly used for males with metastatic prostate cancer
nor any systemic medications prescribed for our patient.
Because of the dependence of most prostate cancers on testosterone, hormone
therapy is used throughout various stages of prostate cancer. Our patient was
prescribed the recommended dosage of enzalutamide, which is 160 mg/day.9 Oral
enzalutamide has been generally well tolerated in randomized controlled trials.9 As
seen in Table 2, enzalutamide has not been shown to have ocular side effects.9 It is
only recommended to use enzalutamide with caution in patients with a history of
seizure, known cardiovascular risk factors and/or those who experience ischemic
events.
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Common
adverse Less common reactions
reactions
(1% to <10%):
(>10%):
Asthenia/fatigue
Nonpathologic fractures
Hot flush
Anxiety
Headache
Memory impairment
Hypertension
Dry skin
Pruritus
Gynecomastia

Rare reactions
(less than 1%):
Seizure
Ischemic heart disease

Table 2: Oral enzalutamide adverse reactions

Leuprolide acetate for injectable suspension (Eligard®) is used to treat the
symptoms associated with advanced prostate cancer.10 Leuprolide acetate is the first
luteinizing hormone-releasing hormone agonist commercially available that
extends treatment for 6 months.11 It rapidly suppresses testosterone levels; after 1
month of treatment, 97% of patient had a testosterone level less than 50 ng/dl.10
The mean time to testosterone suppression to 50ng/dl was 21.2 days.10 A 12-month,
multi-center clinical study was completed to investigate leuprolide acetate.10 The
most common adverse events include hot flashes, asthenia, and gynecomastia.10 No
ocular side effects were reported during this clinical study. 10
To aid in analyzing the role of systemic medications on retinal findings, the
Naranjo adverse drug reaction probability (ADR) scale was utilized.11 To separate
any interaction between enzalutamide and the Eligard® injection, both medications
were scaled individually. Both medications received the same score and deemed
as possible adverse drug reactions. For injectable medications like leuprolide
acetate, the ADR scale may have some limitations. Unlike oral medications, an
injected medication with a 6-month effect cannot be easily withdrawn. Thus, the
scale should be cautiously interpreted for this case.
Radiation has been known to yield adverse ocular effects. Radiation retinopathy
has been reported following local plaque radiation and external beam radiation for
the treatment of ocular and periocular conditions such as choroidal melanoma,
choroidal metastases from breast carcinoma, nasopharyngeal carcinoma, periorbital
basal cell carcinoma, and intracranial lesions.12 The manifestations of radiation
retinopathy are frequently likened to the retinal vascular abnormalities of diabetic
retinopathy such as microaneurysms, retinal hemorrhages, capillary non-perfusion,
and infarcts of the nerve fiber layer.12 Macular changes such as hard exudates,
macular edema, and serous detachment have also been reported.12 These macular
changes, although less common, have the potential of leading to macular hole
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formation. In our case, the patient’s radiation treatments targeted the prostate and
lower back, and therefore, less likely to have resulted in ocular complications.
Treatment of full-thickness macular holes begins with a referral to a retinal
specialist. Superior surgical results are usually achieved in smaller lesions present
for under 6 months; however, some substantial visual improvement has been seen
in longstanding cases.1 Referral is typically made within several weeks, sooner if
quality of life is affected. The surgical treatment requires a vitrectomy combined
with a peeling of the internal limiting membrane to relieve vitreomacular traction,
and gas tamponade placement.1 The need for extended face down positioning
following the surgical repair has been questioned in recent years.1 Our patient was
referred for surgical treatment at his initial visit due to the impact the bilateral
condition had on his activities of daily living. Given the patient’s systemic health
and potential effects of his chemotherapy treatment on his ocular health, surgical
treatment was postponed until there was a break in chemotherapy treatment. After
surgical treatment of the first eye, the large full-thickness macular hole was
successfully closed. Vitrectomy with membrane peel and gas tamponade for the
second eye was planned for the next break in his chemotherapy treatment.
CONCLUSION
Full-thickness macular holes can have a major impact on quality of life due to
their rapid and significant impact on central vision. This is especially true on the
rare occasion that they occur bilaterally. Most full-thickness holes occur
unilaterally, secondary to vitreomacular traction, with occasional involvement of
the fellow eye months to years later. The occurrence of simultaneous, bilateral fullthickness macular holes is rare, forcing the clinician to investigate other risk factors.
Our patient developed full-thickness macular holes while undergoing
chemotherapy and radiation treatments for metastatic prostate cancer. However,
lacking further scientific evidence, we cannot conclude that chemotherapy agents
or radiation were directly related to the simultaneous development of bilateral fullthickness macular holes in our patient. As the prevalence of prostate cancer
increases and these medications become more widely used, more adverse reactions
may be seen in the future. The prescribing physician should consider reporting
adverse reactions to the drug monitoring board in these cases. This case emphasizes
the importance of a comprehensive health history, prompt diagnosis and
communication between specialists. Fortunately, with timely referral and
treatment, surgical repair can be quite impactful for these patients.
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